Showing results (231-240 of 536) with videos related to
Sort By:
Pageof 54
Lancet (London, England)|December 10, 2013
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and futureSteven E Kahn, Mark E Cooper, Stefano Del PratoCurrent Atherosclerosis Reports|April 8, 2004
Use of genetic mouse models in the study of diabetic nephropathyTerri J Allen, Mark E Cooper, Hui Y LanAnnals of the New York Academy of Sciences|May 2, 2008
Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?Karly C Sourris, Josephine M Forbes, Mark E CooperExpert Opinion on Therapeutic Targets|October 11, 2022
Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related moleculesJiali Tang, Fang Liu, Mark E Cooper, et al.Expert Opinion on Therapeutic Targets|June 4, 2019
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapiesAnnabelle M Warren, Søren T Knudsen, Mark E CooperExpert Opinion on Pharmacotherapy|April 28, 2015
Recent advances in glucose-lowering treatment to reduce diabetic kidney diseaseNordin M J Hanssen, Nicholas Russell, Mark E CooperFASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 6, 2013
Ubiquitin-specific protease 2-69 in macrophages potentially modulates metainflammationHiroshi Kitamura, Shunsuke Kimura, Yoshinori Shimamoto, et al.Genome Research|April 16, 2014
Vascular histone deacetylation by pharmacological HDAC inhibitionHaloom Rafehi, Aneta Balcerczyk, Sebastian Lunke, et al.Non-Coding RNA|January 25, 2022
The Non-Coding RNA Journal Club: Highlights on Recent Papers-10Jairo A Pinzon Cortes, Assam El-Osta, Giulia Fontemaggi, et al.Diabetes|October 19, 2019
Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic AgilitySih Min Tan, Mark Ziemann, Vicki Thallas-Bonke, et al.Pageof 54